Ruxolitinib Benefits Some Patients with Graft | 合法藥品大搜索

2020年5月29日—Graft-versus-hostdiseasecandevelopafteratransplantofstemcells...Thisspecificitycouldcontributetothelimitedsideeffectsobservedin ...

May 29, 2020, by NCI Staff

Graft-versus-host disease can develop after a transplant of stem cells (round objects) from a donor.

Credit: iStock

Patients with blood cancers who develop graft-versus-host disease (GVHD) within the first few months after receiving a stem cell transplant and don’t respond to steroids are more likely to respond to the drug ruxolitinib (Jakafi)[1] than to other treatments, according to results from a large clinical trial.

The findings are from the first randomized clinical trial[2] of a treatment for GVHD[3] to yield positive results. And the study confirms findings from a smaller trial that, in 2019, led to the approval of ruxolitinib by the Food and Drug Administration (FDA) for some ...